Your search for non small cell lung cancer returned 484 results

Cancer patients with biomarker-positive tumors have better outcomes on immune checkpoint inhibitor therapy, a meta-analysis suggests.

A regulatory decision is expected on November 27, 2023.

Reviewers discussed new and conventional therapies for lupus nephritis and the prospect of precision medicine.

Improvement seen compared with chemotherapy alone for first-line treatment of advanced non-small cell lung cancer.

Amivantamab can provide a long-term benefit in NSCLC patients with EGFR exon 20 insertions whose disease progressed on platinum-based chemotherapy, a study suggests.

Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody.

Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.

The designation is supported by data from the ongoing phase 2 KEYNOTE-942 study, which included 157 patients with stage III/IV melanoma following complete resection.

Eight of nine patients with major pathological response (MPR) were alive and disease-free at five years, while six of 11 without MPR experienced relapse

High drug prices and ongoing shortages may prompt cancer patients to buy treatments online and fall prey to illegitimate pharmacies.